Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Other Non-Current Liabilities (2020 - 2023)

Historic Other Non-Current Liabilities for Journey Medical (DERM) over the last 4 years, with Q2 2023 value amounting to $1.5 million.

  • Journey Medical's Other Non-Current Liabilities fell 6087.18% to $1.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.5 million, marking a year-over-year decrease of 6087.18%. This contributed to the annual value of $1.4 million for FY2022, which is 6106.98% down from last year.
  • Per Journey Medical's latest filing, its Other Non-Current Liabilities stood at $1.5 million for Q2 2023, which was down 6087.18% from $1.4 million recorded in Q1 2023.
  • Journey Medical's Other Non-Current Liabilities' 5-year high stood at $8.1 million during Q4 2020, with a 5-year trough of $1.4 million in Q3 2022.
  • For the 4-year period, Journey Medical's Other Non-Current Liabilities averaged around $3.3 million, with its median value being $3.6 million (2021).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 5542.58% in 2021, then tumbled by 6852.23% in 2022.
  • Journey Medical's Other Non-Current Liabilities (Quarter) stood at $8.1 million in 2020, then tumbled by 55.43% to $3.6 million in 2021, then plummeted by 61.07% to $1.4 million in 2022, then rose by 5.52% to $1.5 million in 2023.
  • Its Other Non-Current Liabilities stands at $1.5 million for Q2 2023, versus $1.4 million for Q1 2023 and $1.4 million for Q4 2022.